Claims for Patent: 8,722,657

Summary for Patent: 8,722,657

Title:	Salts and crystalline forms of an apoptosis-inducing agent
Abstract:	Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin- -1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfon- yl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
Inventor(s):	Catron; Nathaniel (Vernon Hills, IL), Chen; Shuang (Gurnee, IL), Gong; Yuchuan (Waukegan, IL), Zhang; Geoff G. (Vernon Hills, IL)
Assignee:	Abbvie Inc. (North Chicago, IL)
Application Number:	13/301,257
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,722,657
Patent Claims:	1. A compound 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin- -1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfony- l)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (Compound 1) in a crystalline form wherein the crystalline form is Compound 1 free base anhydrate, characterized by a powder X-ray diffraction pattern having five or more peaks selected from those at 6.3, 7.1, 9.0, 9.5, 12.5, 14.5, 14.7, 15.9, 16.9, and 18.9 degrees 2.theta. (pattern A), each peak being .+-.0.2 degrees 2.theta., when measured at about 25.degree. C. with Cu K.sub..alpha. radiation at 1.54178 .ANG.. 2. A pharmaceutical composition comprising the compound in said crystalline form of claim 1 and one or more pharmaceutically acceptable excipients. 3. A process for preparing a pharmaceutical solution comprising dissolving the compound in said crystalline form of claim 1 in a pharmaceutically acceptable solvent or mixture of solvents.